Soft drugs active metabolite-based

Figure 5. Metabolism of metoprolol (8). a well-known p-blocker. and design of soft drugs (13) based on the inactive metabolite 12. Activity, metabolism, and distribution properties can be controlled via modification of the R (or some other) substituents and via modification of the distance between the aromatic ring and the ester function (77). Esmolol (20) is an USA P-blocker already approved for intravenous clinical use. while adaprolol (16) has reached clinical trials.

---